SLC6 Transporter Folding Diseases and Pharmacochaperoning.
Handbook of experimental pharmacology January 1, 2018 Michael Freissmuth, Thomas Stockner, Sonja Sucic 44 citations
Mutations in solute carrier 6 (SLC6) family transporters cause misfolding and lead to diseases such as infantile dystonia (from dopamine transporter mutations), mental retardation (from creatine transporter mutations), and hyperekplexia (from glycine transporter mutations). Compounds that correct these folding defects, known as pharmacochaperones, were first discovered in serotonin transporter mutants, where ibogaine and its metabolite noribogaine were found to rescue folding-deficient mutants. Additional compounds have since been identified that restore function in dopamine transporter mutants. These agents not only offer therapeutic potential for affected children but also serve as tools to study transporter folding, potentially enabling the rational design of pharmacochaperones.